Skip to main content
    T

    Telomir Pharmaceuticals, Inc. Common Stock (TELO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.05
    +0.00 (+0.00%)

    Market Cap: $77.30M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(3/5)
    Avg Surprise
    -22.21%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.03
    Range$-0.03 - $-0.03
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current$-0.03
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-$-0.03---
    Jun 26
    Reported Aug 13
    		$-0.79N/AN/ABeat-364.7%
    Mar 26
    Reported May 14
    		$-0.03N/AN/ABeat+58.9%
    Dec 25
    Reported Mar 17
    		$-0.06$-0.07+14.29%Beat+40.0%
    Sep 25
    Reported Nov 10
    		$-0.03N/A+57.14%Beat+85.2%
    Jun 25
    Reported Aug 14
    		$-0.17$-0.08-112.50%Miss-247.6%
    Mar 25
    Reported May 14
    		$-0.07$-0.10+30.00%Beat+68.9%
    Dec 24
    Reported Feb 4
    		$-0.10$-0.05-100.00%Miss-
    Sep 24
    Reported Nov 12
    		$-0.20N/AN/ABeat-
    Jun 24
    Reported Aug 13
    		$-0.05N/AN/ABeat-
    Mar 24
    Reported May 13
    		$-0.23N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.16EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-213.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-699.09x
    Current Ratio16.14xQuick Ratio16.14x
    Trading Statistics
    Beta-0.30Avg Volume146.52K
    52-Week High$1.7052-Week Low$0.89

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.13
    SMA 20$1.17
    SMA 50$1.15
    SMA 200$1.24
    EMA 10$1.11
    EMA 20$1.14
    EMA 50$1.16
    EMA 200$1.29

    MACD

    Line: -0.03Signal: -0.01Hist: -0.02

    ADX

    ADX: 31.9+DI: 31.0-DI: 15.3

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down100.0
    PSAR$1.43

    Bollinger Bands

    Upper Band$1.29
    Lower Band$1.05
    %B Position2113%(Upper)
    Band Width0.02

    RSI (14-Day)

    Neutral
    35.6

    Momentum Oscillators

    Stoch %K4.5
    Stoch %D3.5
    Williams %R-93.0
    ROC (10d)-10.3%
    Momentum-0.12
    CCI (20d)-173.0
    MFI (14d)71.5

    Volatility Measures

    ATR (14d)$0.08(7.9%)
    StdDev (20d)0.06
    Hist Vol53.3%(High)

    Volume Flow

    VWAP$1.04
    OBV181.9M
    AD Line-122.1M
    CMF (20d)-0.403

    Volume Metrics

    Avg Vol (20d)151.6K
    Vol Ratio0.5x(Low)
    VWMA (20d)$1.19

    Pivot Points

    R3$1.17
    R2$1.14
    R1$1.09
    Pivot Point$1.06
    S1$1.02
    S2$0.99
    S3$0.94

    Advanced Oscillators

    TSI-13.52
    Ultimate Osc29.7
    KST-18.81

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$18.79M$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/A$9.40M$6.01M$1.47M$1.92MN/AN/A
    Gross ProfitN/AN/AN/AN/AN/AN/A$9.40M$-6,006,178$-1,474,496$-1,916,064N/AN/A
    Operating Expenses$1.76M$1.04M$2.13M$1.15M$5.07M$2.19M$2.91M$6.01M$1.47M$1.92M$1.08M$954,153
    R&D$444,674$467,797$1.30M$759,525$42,839$336,996$269,083$627,434$594,801$804,023$203,784$262,562
    SG&A$1.32M$573,539$838,472$386,951$5.03M$1.85M$2.64M$5.38M$879,695$741,541$395,290$102,191
    Operating Income$-1,764,676$-1,041,336$-2,134,681$-1,146,476$-5,069,910$-2,187,782$-2,905,435$-6,006,178$-1,474,496$-1,916,064$-1,078,624$-954,153
    Interest Income$46,176$51,644$72,100$44,182$1,362$8,000$7,061$15,445$25,493$0$0$0
    Interest Expense$3,028$1,255$1,388$2,730$1,342$7,954$1$0$0$4.34M$761,824$757,173
    Income Before Tax$-1,721,528$-990,947$-2,061,193$-1,102,294$-5,069,890$-2,179,828$-2,898,373$-5,990,733$-1,449,003$-6,254,607$-9,327,215$-1,711,326
    Income Tax Expense$0$0$0$0$0$0$0$0$0$-1,916,064$-1,078,624$-954,153
    Net Income$-1,721,528$-990,947$-2,061,193$-1,102,294$-5,069,890$-2,179,828$-2,898,373$-5,990,733$-1,449,003$-6,254,607$-9,327,215$-1,711,326
    EBITDA$-1,718,500$-989,692$-2,062,581$-1,099,564$-5,068,548$-2,179,828$-2,898,374$-5,990,733$-1,423,510$-1,916,064$-8,565,391$-954,153
    EBIT$-1,718,500$-989,692$-2,062,581$-1,102,294$-5,069,910$-2,188,000$-941,374$-5,990,733$-1,449,003$-3,832,128$-8,565,391$-1,908,306
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TELO

    News

    InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Raises Approximately $5.6 Million in PIPE Financing

    Telomir Pharmaceuticals (NASDAQ: TELO) has successfully raised approximately $5.6 million through a private investment in public equity (PIPE) financing. The funding...

    StreetInsider•10/8/26•Somewhat-Bullish

    Telomir raises $5.6M in common stock financing for cancer drug

    Telomir Pharmaceuticals, Inc. announced it has raised approximately $5.6 million through a private investment in public equity financing. The funds, which include a $1.0 million investment from John Paul DeJoria...

    Investing.com Nigeria•10/6/26•Bullish

    Telomir raises $5.6M in common stock financing for cancer drug

    Telomir Pharmaceuticals, Inc. announced it raised approximately $5.6 million through a private investment in public equity financing by issuing common stock. The proceeds will primarily support the clinical development...

    Investing.com•10/6/26•Bullish

    Telomir raises $5.6M in PIPE financing with DeJoria adding $1M

    Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has secured approximately $5.6 million in PIPE financing through the issuance of common stock at $1.16 per share. This financing includes a $1.0 million investment from...

    StreetInsider•10/6/26•Bullish

    Telomir Pharmaceuticals Raises $5.6 Million PIPE; Issues Placement Agent Warrants

    Telomir Pharmaceuticals successfully raised approximately $5.6 million through a private placement of common shares...

    TradingView•10/6/26•Bullish

    TELO Valuation and Fair Value

    P/E
    -1.2x
    P/B
    7.2x
    See GNG's fair value

    TELO Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -213.1%

    TELO Competitors

    CompanyTicker
    Pelthos Therapeutics Inc.PTHS
    Nutriband IncNTRB
    Kazia Therapeutics Ltd ADRKZIA
    NeOnc Technologies Holdings, Inc. Common StockNTHI
    Lixte Biotechnology Holdings IncLIXT
    Cognition Therapeutics IncCGTX
    Cardiff Oncology IncCRDF
    Electrocore LLCECOR

    Sector: Healthcare

    TELO Earnings: Beat Rate and Next Report

    Beat rate
    4 of 6 quarters (66.7%)
    Average surprise
    -31.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.03
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About TELO

    Does TELO pay dividends?

    Telomir Pharmaceuticals, Inc. Common Stock (TELO) does not currently pay a regular dividend.

    What is TELO's market cap?

    Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a market capitalization of $77.30M with a current stock price of $1.05.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In